Dr. Max, a leading European pharmacy chain, has acquired several pharmacies in Italy as part of its expansion strategy supported by its owner, the Penta Group.
Information on the Target
Dr. Max is one of the largest pharmacy chains in the European Union, recognized as a market leader in the Czech Republic and Slovakia. It is also among the largest pharmacy networks in Poland, operating approximately 2,000 pharmacies and serving over 230,000 customers daily. In 2017, Dr. Max recorded sales of €1.2 billion, demonstrating its significant presence in the pharmaceutical retail market.
Owned by the Penta Group, a major investment fund in Central Europe, Dr. Max benefits from extensive financial backing. The Penta Group operates across various sectors, including retail and healthcare, with an annual revenue of €5.6 billion and a presence in countries such as Germany, Austria, the Czech Republic, Slovakia, and Poland.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Target’s Specific Country
The pharmaceutical industry in the Czech Republic has seen robust growth, primarily driven by increasing health awareness and a rising demand for over-the-counter and prescr
Similar Deals
CARSO Group → Agro.biolab Laboratory
2023
Dr. Max
invested in
Farmacia Nuova della D.ssa Fantoni Beatrice e del Dott. Lodovichi Andrea & C. S.n.c., Farmacia del Vivo, Farmacia dell’Ospedale di Lavagnini D.ssa Marta e C. S.a.s.
in 2023
in a Buy & Build / Roll-Up deal
Disclosed details
Revenue: $1,304M